Unveiling the Hidden Risks: An Update Decade-Long Analysis of Abraxane-Related Adverse Events from the FAERS Database

Area of Science:

• Oncology
• Pharmacovigilance
• Drug Safety

Background:

• Abraxane (nanoparticle albumin-bound paclitaxel) is a key chemotherapy for breast, lung, and pancreatic cancers.
• While effective, Abraxane is associated with adverse events (AEs) requiring monitoring.

Purpose of the Study:

• To evaluate the adverse event (AE) profile of Abraxane.
• Utilize recent data from January 2004 to December 2023 from the FDA Adverse Event Reporting System (FAERS).

Main Methods:

• Extracted Abraxane-related AE data from the FAERS database.
• Calculated Reporting Odds Ratios (ROR) and Proportional Reporting Ratios (PRR) to assess AE associations.

Main Results:

• Identified 10,310 Abraxane AE reports.
• Most frequent AEs: blood/lymphatic (ROR 6.44), hepatobiliary (ROR 3.16), infections (ROR 1.45), gastrointestinal (ROR 1.42).
• New AEs noted: scleroderma-like reactions (ROR 95.4), vascular pseudoaneurysm ruptures (ROR 87.71).

Conclusions:

• FAERS analysis provides updated safety information for Abraxane.
• Highlights the need for continuous pharmacovigilance and further investigation into specific AEs.
• Emphasizes the importance of a robust post-marketing surveillance system for Abraxane safety.